Villeroy & Boch AG

  • WKN: 765723
  • ISIN: DE0007657231
  • Land: Germany

Nachricht vom 29.09.2021 | 18:44

Villeroy & Boch AG: Villeroy & Boch raises its annual forecast for 2021 again

Villeroy & Boch AG / Key word(s): Change in Forecast
Villeroy & Boch AG: Villeroy & Boch raises its annual forecast for 2021 again

29-Sep-2021 / 18:44 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Villeroy & Boch raises its annual forecast for 2021 again

Mettlach, 29.09.2021 - Following the strong first half-year and the sustained positive business development in the 3rd quarter of 2021, the Management Board of Villeroy & Boch AG has again raised its turnover and earnings forecast for the full year today. Villeroy & Boch now expects an increase in group turnover to over EUR 920 million (previous forecast: around EUR 885 million) and a group operating result of over EUR 85 million (previous forecast: over EUR 75 million). The renewed increase in the earnings forecast is based on the higher turnover expectation for 2021.

Note: The interim report for Q3 2021 will be published as scheduled on 20 October 2021 and will contain detailed information on the business development in both divisions.

Press Relations contact:
Katrin May
Head of PR
Tel.: +49 (0) 68 64 - 81 27 14

Investor Relations contact:
Susanne Reiter
Head of Corporate Treasury and Investor Relations
Tel.: +49 (0) 68 64 81 12 27

29-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021